Media Contact
Kelly Zitlow, 847-858-5230

Discovery Life Sciences Acquires QualTek

Discovery Life SciencesTM (Discovery) today announced the acquisition of QualTek Molecular Laboratories (QualTek), a renowned provider of immunohistochemistry (IHC) services with CAP/CLIA-accredited and Good Laboratory Practice-(GLP) capable laboratories in California and Pennsylvania, respectively.

QualTek  significantly augments Discovery’s existing histopathology services and creates a uniquely powerful suite of solutions that include one of the world’s largest commercial biorepositories and biospecimen procurement networks, the HudsonAlpha Discovery sequencing and bioinformatics laboratory, and innovative flow cytometry and cell-based laboratory services.

The science of IHC is crucial for the identification and validation of tissue biomarkers that inform decision making throughout drug and diagnostic research and clinical development.  Drug and diagnostic development programs in Oncology depend on the use of specific and sensitive biomarkers that help scientists define diagnostic and treatment options for specific patient populations and understand the underlying biological processes driving both disease progression and the potential benefits of the targeted therapies under development.

Discovery’s integrated, holistic approach to biomarker validation starts by accelerating the earliest stages of preclinical research via access to its millions of biospecimens and the provision of a broad range of multiomic annotation services. The acquisition of the QualTek  team adds innovative assay development and validation capabilities combined with the knowledge and expertise to utilize any of the the major IHC technology platforms.  The QualTek team continues to build on its successful track record of supporting clinical trial design and providing the follow-on centralized clinical trial IHC laboratory services; the expert team at QualTek developed the prototype PD-L1 companion diagnostic assay that provided the  foundation for development of the companion diagnostic for pembrolizumab.

“We founded QualTek 22 years ago and have successfully realized our vision of using IHC as a platform for personalized medicine to help increase cancer patient response to therapy,” said Frank Lynch, PhD, COO of QualTek. “We can now leverage direct access to the largest bank of annotated FFPE blocks to allow our biopharma partners to design clinical trials strategically, based on understanding the expression of their target proteins in specific patient populations.”

“This knowledge can save millions in cost, years of time, and help drive successful development programs that change patients’ lives,” added Steve Bernstein, PhD, CEO of QualTek. “QualTek is proud and excited to join Discovery Life Sciences and bring the advantage of our scale and synergies to accelerate the research and development of our clients’ drugs and companion diagnostics.”

“All of Discovery’s services provide access to leading edge science, technologies, quality and speed. Our clients rely on us to accelerate their decision making as they move along the path that begins in research and extends through clinical development,” said Glenn Bilawsky, Discovery’s CEO.  “The expertise and scale of our new immunohistochemistry capabilities, alongside our leading biospecimen, flow cytometry, and genomic services, uniquely enable us to deliver meaningful answers that our clients can trust to develop innovative drugs and diagnostics faster and more cost-effectively.”

 About Discovery Life Sciences 

Discovery Life Sciences is the global market leader in biospecimen analysis, procurement, distribution, and genomic, cell-based and histology-based scientific services for the pharmaceutical, biotechnology, and diagnostics industries. HudsonAlpha Discovery is Discovery’s sequencing and bioinformatics division, a globally recognized service laboratory that leverages the most current genomic research technologies to comprehensively support discovery, translational, and clinical research. Driven by science, the Discovery team engages with customers in an innovative, consultative approach to overcoming obstacles and reaching a faster end result. We are Science at your Service™! For more information, visit




EVERSANA Announces Agreement to Acquire Cornerstone Research Group

EVERSANA™, the leading independent provider of commercial services to the life science industry, today announced an agreement to acquire Canada-based Cornerstone Research Group, Inc.

Headquartered in Burlington, Ontario with an additional location in Sydney, Nova Scotia, Cornerstone Research Group is the leader in Health Economics and Outcomes Research (HEOR) services, working with leading pharmaceutical and medical device companies across the globe.

EVERSANA offers a fully integrated and independent commercial services platform designed to solve global pricing, access, reimbursement, adherence and product delivery challenges in the life science sector. With the acquisition of Cornerstone Research Group, EVERSANA adds comprehensive HEOR capabilities at a global scale, including economic modeling, evidence synthesis, value communication, and reimbursement strategies across all stages of the product lifecycle.

“Pharmaceutical companies face strong pressures to quickly assess and quantify both the direct and indirect value of their in-market products and development pipeline,” said Jim Lang, CEO. “By adding a strong health economics and outcomes capability to our integrated commercial platform, we can now conceptualize, deliver and measure value at every stage of the product lifecycle from clinical trials to ongoing patient adherence. The Cornerstone Research Group team brings tremendous expertise that will deliver immediate value to our clients worldwide, and we’re thrilled to have them on board.”

Cornerstone Research Group will transition to the EVERSANA brand in the coming quarter, and the company’s partners, Chris Cameron, Daniel Grima and Melissa Thompson will assume leadership roles at EVERSANA.

“We’re excited to join the EVERSANA family,” shared Thompson. “The need for evidence-based research has never been greater than in today’s pharmaceutical industry. EVERSANA’s integrated platform gives our current clients immediate access to expanded services and solutions, and we also see tremendous opportunities to bring HEOR services to current EVERSANA clients. Additionally, for our employees, EVERSANA is the perfect cultural fit and provides a promising future for all.”

Financial details of the acquisition are not being disclosed.


EVERSANA™ is the leading independent provider of global services to the life science industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product lifecycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies to advance life science solutions for a healthier world. To learn more about EVERSANA, visit or connect through LinkedIn and Twitter.

About Cornerstone Research Group

Cornerstone is a global health economic and market access research company supporting pharmaceutical and medical device companies. Founded in 2005, Cornerstone’s initial focus was to build on the partners’ experience in health economic research with an emphasis on global cost-effectiveness models and Canadian reimbursement submissions.  Since that time, the company has strategically grown to add a world-class evidence synthesis and data analytics team; develop outstanding payer communication capabilities; and support global programs with submissions in all major markets. For more information, visit





CATO Research Announces Merger

Cato Research, LLC (CATO) announced today that it has merged with Specialized Medical Services-oncology BV (SMS-oncology) to bolster its portfolio of global solutions dedicated to supporting life science organizations with advancing drug development.  The combined company will transition to the new name, CATO SMS, in the coming year.

By joining forces, CATO and SMS-oncology expand their presence across Europe and North America, deepen their oncology and regulatory expertise, and broaden their suite of services. Headquartered in Schiphol, the Netherlands, SMS-oncology is one of the few full-service contract research organizations (CROs) in the world dedicated to oncology.  The boutique CRO’s deep expertise in designing and executing complex oncology and immuno-oncology trials complements CATO’s regulatory knowledge and drug development services.

“CATO and SMS-oncology bring a powerful blend of capabilities focused on supporting small and mid-sized biotech and pharmaceutical companies with their innovative research.  Our companies share strong cultural values, anchored by a commitment to high quality and personalized customer service.  Together, we’re focused on growing and enhancing our services to build an industry-leading company specializing in complex therapeutic areas, including oncology, cell and gene therapy, and rare treatments,” said Mark A. Goldberg, M.D., executive chairman, CATO.

Philine van den Tol, CEO, SMS-oncology, added, “Coming together with CATO is an important step toward our objective of providing clients with a broader set of solutions supported by the high-touch service that they expect from us.  We can now offer our clients an expanded geographic footprint in the United States and Canada, as well as additional access to valuable drug development and regulatory expertise.  We’re especially excited to engage CATO’s expertise in working with the FDA.”

Ms. Van den Tol and the management team will continue to lead SMS-oncology's operations. Dr. Goldberg will serve as executive chairman of the combined entity.  CATO and SMS-oncology will operate under their respective brands until the transition to their new name, CATO SMS, is complete.

CATO’s merger with SMS-oncology is the latest step in the company’s strategic expansion since Water Street Healthcare Partners and JLL Partners invested in the company last year. The health care investors recently announced the acquisition of THREAD, a provider of innovative technology that enables virtual research.  CATO can engage THREAD on opportunities where clients want to leverage its platform to modernize their clinical studies and registries through technology-enabled interactions.

Financial terms of the merger are not being disclosed.  Achelous Partners LLC served as financial advisers to SMS-oncology on the merger.

About SMS-oncology

SMS-oncology is Europe’s leading full-service CRO solely dedicated to oncology. With its unique business model of integrating oncology drug development affairs and clinical operations, SMS-oncology covers the whole value chain from trial design to setup, management and completion of phase I to IV oncology trials. With nearly 100 employees, SMS-oncology operates in more than 20 countries from its headquarters, located near Schiphol Airport in the Netherlands and EMA in Amsterdam, as well as locally from Belgium, Germany, Spain and the Nordics. SMS-oncology nurtures a high-performance culture; its dedicated team of professionals thrive on accomplishing operational excellence, extraordinary results, and cooperating toward the goals and milestones of its clients. Please refer to

 About Cato Research

Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research specializes in drug development support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of more than 200 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients’ products to market with speed and cost-effectiveness.  For more information about Cato Research, visit


Discovery Becomes Global Center of Excellence for PacBio Long-Read Genomic Sequencing

Discovery Life Sciences™(Discovery) announced today its substantial investment in long-read genomic sequencing technology from Pacific Biosciences (PacBio).

The instrumentation will complement the existing infrastructure of HudsonAlpha Discovery™, Discovery’s genomic sequencing and bioinformatics division.  HudsonAlpha Discovery will continue to scale sequencing over a range of technologies, creating the most comprehensive infrastructure to support the most accurate and complete analysis of complex genomic and transcriptomic projects possible. This investment creates a PacBio® Center of Excellence for long-read sequencing.

Existing short-read sequencing is like a complex jigsaw puzzle. Researchers align and merge many short DNA sequences to reconstruct a representation of the reference genome, but the alignment and assembly from short reads has limitations. Long-read sequencing provides additional power and context; recent studies show that it detects structural variants in disease genes that are missed by previous methods. Combining short- and long-read sequencing creates a depth and breadth to comprehensively understand the complex genomics driving cancer and other diseases.

The multiple PacBio Sequelâ II Systems that Discovery is acquiring provide highly accurate long reads and supplement HudsonAlpha Discovery’s existing short-read platforms to add resolution across both DNA and RNA applications. In addition to whole genome sequencing for variant detection, the Sequel II Systems will provide high-volume capacity for long-read RNA sequencing of gene isoforms. These sequencing services, combined with the HudsonAlpha Discovery proprietary methods for long-fragment RNA isolation from FFPE and access to millions of FFPE biospecimens, deliver a novel set of applications to the entire genomics community.

Most cancer biospecimens are stored in a Formalin-Fixed, Paraffin-Embedded (FFPE) format, and Discovery has the largest global inventory—millions of high-quality FFPE biospecimens.  HudsonAlpha Discovery is committed to extracting the highest resolution data from those specimens and has developed a proprietary methodology to extract long transcripts from FFPE materials. The investment in the Sequel II System will be used to characterize these transcipts for gene fusions, RNA modifications, and other structural alterations that are best resolved with long-read sequencing.

“This investment enables HudsonAlpha Discovery to conduct long-read sequencing of thousands of high-quality human genomes per year. We’ve developed methods to significantly improve the integrity of RNA isolated from FFPE; now we are marrying the PacBio technology with our proprietary method to improve our ability to see the RNA transcripts in cancer biology,” said Shawn Levy, PhD, Discovery’s chief scientific officer, Genomics. “With these holistic solutions, Discovery is uniquely positioned to help researchers advance their understanding of complex diseases by providing a single partner from specimen selection to short- and long-read sequencing and, finally, to data interpretation and actionable result delivery.”

"We are pleased to be working closely with Discovery Life Sciences as they set up the highest-throughput PacBio Sequencing facility in the world with a goal to advance disease research and population studies," said Jonas Korlach, PhD, chief scientific officer at Pacific Biosciences. “We continue to aggressively invest in our laboratory resources to support the rapid advancement of our clients’ research timelines and objectives,” said Glenn Bilawsky, Discovery’s CEO. “Our long-read sequencing services will provide the market with a single source to derive high-quality data from our PacBio systems, in combination with our other offerings in sequencing, cell-based, immunohistochemistry services.  Discovery is the first to bundle this combination of scientific services and technology platforms alongside one of the largest global biospecimen inventories under one brand.”

About Discovery Life Sciences 

Discovery Life Sciences is the global market leader in biospecimen analysis, procurement, distribution, and scientific services for the pharmaceutical, biotechnology, and diagnostics industries. HudsonAlpha Discovery is Discovery’s sequencing and bioinformatics division, a globally recognized service laboratory that leverages the most current genomic research technologies to comprehensively support discovery, translational, and clinical research. Driven by science, the Discovery team engages with customers in an innovative, consultative approach to overcoming obstacles and reaching a faster end result. We are Science at your Service™! For more information, visit




Viant Acquires Meraqi Medical

Viant, a leading global services provider to the medical device industry, announced today that it has acquired Meraqi Medical.  It is the fourth acquisition that Viant has completed in two years to expand its clinical market expertise, global footprint, and portfolio of solutions.

Headquartered in Silicon Valley, Meraqi extends Viant’s expertise in front-end design and development for interventional technologies and bioelectronics, and expands Viant’s platform within minimally invasive surgical devices. Meraqi also adds a West Coast design and development (D&D) hub to Viant’s East Coast D&D Center and global network of manufacturing sites. Viant will incorporate Meraqi’s engineering expertise and design capabilities into its suite of solutions that support customers with expanding their product offerings, optimizing their supply chains, and improving quality while managing costs.

“Meraqi stands out for its deep technical knowledge, passion for innovation and agility to help customers advance their technologies,” said Declan Smyth, president of Franchise, Viant. “Adding Meraqi’s expertise to Viant’s breadth of capabilities and global scale provides our customers with expanded access to end-to-end solutions for all their medtech needs.”

“Joining Viant will give our customers access to a world class, quality focused organization with global manufacturing facilities and scale,” said founder Al Hershey. “Additionally, this will enable Meraqi to accelerate the expansion of our capabilities and better serve our customers. Our shared passion for supporting innovative devices to address unmet patient needs and loving what we do makes this a very exciting time for our two companies and for our customers.”

Since partnering with Water Street Healthcare Partners and JLL Partners in 2016, Viant has grown to become one of the world’s premier outsourced manufacturers of medical devices.  The company has expanded its portfolio of design, development, and manufacturing capabilities to offer end-to-end solutions to medical device organizations.  Most recently, Viant announced the appointment of Alton E. Shader, a veteran medical device leader, to chief executive officer to accelerate the company’s strategic expansion.

About Meraqi Medical

Meraqi is a medical device design, development and manufacturing services firm that was established by industry veterans with an unyielding passion for innovation and for servicing customers. With many decades of combined experience, the Meraqi team provides expertise in bioelectronics and interventional and minimally invasive surgical devices. Meraqi provides everything from early brainstorming, concepting, and prototyping to clinical and commercial manufacturing. Meraqi has class 7 & 8 certified cleanrooms and is ISO13485:2016 certified. Learn more at

About Viant

Viant is a global strategic manufacturing partner that helps medical device OEMs bring complex medical devices and components to market. Our deep materials expertise, combined with our experience in design, manufacturing, assembly, and packaging, allow us to bring our customers’ medical technology solutions to life. With nearly 6,000 associates across 24 locations worldwide, we are the perfect combination of big company scale and small company attention. For more information, visit


Water Street Acquires THREAD

Water Street and JLL Partners announced today that they have acquired THREAD, an innovative provider of technology that enables virtual research approaches to modernize clinical studies and registries. Headquartered in Orange County, Calif., THREAD will leverage the investment to accelerate the expansion of its global offering.

THREAD’s platform and services are designed to make clinical trials and registries more accessible and less costly by replacing patient visits at investigator sites with technology-enabled interactions at more convenient locations, including patients’ homes. Growing numbers of biopharma, life science companies, contract research organizations (CROs), and non-profit researchers are engaging THREAD’s virtual research platform to capture clinical study data in between, as well as during or instead of clinic visits.  The company’s platform supports an integrated suite of user-friendly, highly configurable applications that support eConsent, ePRO/eCOA, patient engagement, telehealth virtual visits, site data capture, and medical device and consumer sensor connection.

“Water Street and JLL are the ideal partners for THREAD to accelerate our strategic expansion and solutions to our customers. Their life science expertise and resources will enable us to grow in a thoughtful way that will benefit all of our customers,” said Jeff Frazier, founder and chief executive officer, THREAD.

John Reites, partner and chief product officer, THREAD, added, “We’re excited to expand THREAD’s platform to modernize clinical research for our customers, participants, and sites.  This partnership will further our commitment to make virtual research approaches the standard in studies and registries.”

Water Street and JLL will invest their combined industry experience and network of resources to further develop and expand THREAD’s offering on a global scale. With this support, THREAD will extend its platform to offer customers a broader range of options that can be configured to address their individual needs by engaging components of its technology as standalone point solutions or activating its full suite of capabilities.

Mark A. Goldberg, M.D., a veteran life science leader who has been appointed executive chairman of THREAD, remarked, “THREAD’s platform is highly valued for its user-centric design, flexibility, ease of use, and broad functionality. Working together with our customers, we have the exciting opportunity to advance the next generation of clinical trials to accelerate product development and innovation.”

Last fall, Water Street and JLL invested in CATO Research, a company specializing in drug development support.  Dr. Goldberg, who also serves as executive chairman of CATO, said, “there are many opportunities for THREAD and CATO to collaborate in developing emerging approaches to clinical development.”

THREAD’s leadership team will continue to spearhead the company’s day-to-day operations, and report to Dr. Goldberg. Financial terms of Water Street and JLL’s investment are not being disclosed.


THREAD is a virtual research platform used by biopharma, CROs, non-profit researchers, and life science organizations to capture global clinical study data in between, as well as during and instead of clinic visits. Study sponsors and CROs work with THREAD to provide a more modern and technology-enabled experience for patients, sites, and their study teams. THREAD's platform and supporting services are designed to help customers reduce study launch timelines and budgets with Virtual Visits.  Visit for more information.


Water Street Company Achieves Another FDA Approval

Water Street announced today that its development partnership with a leading medical products company has resulted in the U.S. Food and Drug Administration (FDA) approval of Insulin Human in 0.9% Sodium Chloride Injection (Insulin Human).  It is the first and only ready-to-use insulin for IV infusion.

The new presentation of Insulin Human features an extended shelf life of 30 days at room temperature (77 degrees Fahrenheit /25 degrees Celsius) or 24 months if refrigerated (36 – 46 degrees Fahrenheit/2-8 degrees Celsius) in the original carton to protect from light.  The product is provided in a standardized concentration of 100 units/100 mL in a flexible plastic container.

The approval of Insulin Human marks the eighth drug product successfully developed by Water Street’s company, Celerity Pharmaceuticals, LLC. Celerity funded, developed, and led the approval process of Insulin Human. After gaining FDA approval, Celerity transferred ownership of the product to its medical products company partner.

“We’re honored to be part of successfully developing this innovative presentation of insulin to advance our partner’s goal of introducing medicines in new presentations that help promote clinician efficiency and advance patient care,” said Dan Robins, Ph.D., president, Celerity.


Pathnostics Announces CEO Appointment

Pathnostics, a diagnostic solutions company, announced today that its board of directors has appointed Samuel D. Riccitelli as chief executive officer, effective July 29, 2019.  With more than 30 years of experience in global laboratory services and specialty testing, Mr. Riccitelli will spearhead the fast-growing company’s continued expansion.  He will assume the CEO position from co-founder, David Pauluzzi, who will continue to serve on the board of directors as part of a planned leadership transition.

Mr. Riccitelli began his career as a biomedical engineer before joining Becton, Dickinson and Company,  where he led a patient safety start-up venture.  As executive vice president and chief operating officer at Genoptix, Inc., Mr. Riccitelli directed the company’s rapid growth and successful transformation into one of the world’s leading diagnostic reference laboratories. More recently, he served as president and CEO of Signal Genetics, Inc., a molecular diagnostic company acquired by Quest Diagnostics, Inc. and Miragen Therapeutics, Inc.

“Sam is an entrepreneurial executive who is passionate about building high-growth, high-service laboratory and specialty testing businesses.  His industry knowledge and operations experience will be key to advancing our goal of expanding Pathnostics’ innovative technology into new tests and therapies,” said Mr. Pauluzzi. “It’s been incredible to be part of building Pathnostics from the ground up and Sam is the ideal leader to take our company to the next level.”

Founded in 2014, Pathnostics specializes in diagnostic tests and services across a range of therapeutic areas, including urology, women’s health, and gastroenterology.  The company has grown rapidly in recent years as increasing numbers of specialists have adopted its Guidance test, which uses proprietary molecular technology to simultaneously diagnose and guide antibiotic treatment for complex, recurring urinary tract infections.  Earlier this year, Pathnostics chose to partner with Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, to extend its technology and product portfolio into new tests and therapeutic areas.

“It’s truly a privilege to join Pathnostics and be part of expanding its unique technology to benefit patients in new ways,” said Mr. Riccitelli.  “Dave and the team have established a robust platform that provides substantial opportunity to grow Pathnostics, and I’m eager to begin working with everyone to bring these opportunities to fruition.”

About Pathnostics

Pathnostics is a diagnostic solutions company that pioneers innovative approaches for improved patient care.  Leveraging its proprietary technology, the company develops solutions that address diagnostic and therapeutic issues for physicians and patients.  Headquartered in Irvine, Calif., Pathnostics is a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry.  For more information about the company and its portfolio of products, visit


Key Surgical Signs Agreement to Acquire Insitumed

Key Surgical LLC, a leading global provider of sterile processing and operating theatre supplies, announced today that it has signed an agreement to acquire Hamburg, Germany-based Insitumed GmbH. The strategic acquisition will broaden Key Surgical’s portfolio of endoscopy products and further extend its global footprint.

The acquisition of Insitumed is Key Surgical’s most recent initiative to expand its suite of products and supplies focused on improving patient safety and surgical outcomes. Since merging in 2017 with Interlock Medizintechnik GmbH and Clinipak, Ltd., Key Surgical has grown to serve more than 10,000 hospitals and surgical centres across 70 countries.  The company will add Insitumed’s endoscopy offering to its portfolio of more than 5,000 products and supplies utilized for patient procedures, and cleaning and sterilizing surgical instrumentation.

JV Wulf, president, Key Surgical Europe, said, “Insitumed is highly regarded for its innovative customer-centric product development and its strong relationships with hospital-based endoscopy departments and office-based practices.  Bringing our companies together marks another exciting step forward for Key Surgical, as we continue to broaden and enhance our product offering to benefit our customers and their patients around the world.”

Wolfgang Drews, managing director, Insitumed, added, “We’re pleased to be joining with Key Surgical. Our product offerings are very complementary and together we have an important opportunity to significantly enhance our product offering to customers and extend our reach into new geographic markets.”

Financial terms of the acquisition are not being disclosed.

About Key Surgical

Key Surgical is a leading global provider of sterile processing and operating room supplies. The company offers a broad suite of thousands of products and supplies focused on instrument reprocessing, operating room, and patient procedures to nearly 10,000 facilities in 70 countries. Headquartered in Eden Prairie, Minnesota, Key Surgical is a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. For more information, visit


Viant Appoints Longtime Medical Device Leader to CEO

Viant, a leading global services provider to the medical device industry, announced today that its board of directors has appointed Alton E. Shader to chief executive officer, effective July 15, 2019.  Mr. Shader, who brings more than 20 years of medical device leadership experience to Viant, will spearhead the company’s continued expansion.  He assumes the CEO position from Brian King, who will continue to serve as a senior advisor to the company.

Mr. Shader is highly regarded for driving growth across a range of medical device companies.  As president of Front Line Care for Hill-Rom Holdings, Inc., he spearheaded two major acquisitions, including Welch Allyn, to establish the company’s fastest-growing and most profitable global business. Mr. Shader previously led North America for Hill-Rom, where he designed and implemented a customer-focused commercial organization, which achieved record levels of profitable growth.  Prior to Hill-Rom, Mr. Shader held senior positions in Europe for Baxter International before being promoted to general manager of its U.S. Renal business. He most recently served as president and CEO of Vein Clinics of America.

“Alton’s laser focus on serving the customer, combined with his operational discipline and extensive global experience make him the ideal leader to guide Viant through the company’s next stage of expansion,” said John Greisch, chairman, Viant.  “I want to take a moment to thank Brian for helping us to establish Viant’s strong foundation. We have a tremendous opportunity to build on Viant’s global network of solutions to address the full continuum of our customers’ manufacturing services needs.”

Viant has bolstered its portfolio of manufacturing solutions to the medical technology industry.  Over the past three years, the company has made significant organic investments and completed three strategic acquisitions to become one of the world’s leading outsourced contract manufacturers of medical devices.

“Viant’s commitment to becoming a long-term strategic partner to the world’s leading medical device companies is why I wanted to become part of this organization.  I’m excited to build on Viant’s end-to-end solutions to support our customers by expanding their product offerings, optimizing their supply chains, and improving quality while managing costs on a global scale,” said Mr. Shader.

About Viant

Viant is a global strategic manufacturing partner that helps medical device OEMs bring complex medical devices and components to market. Our deep materials expertise, combined with our experience in design, manufacturing, assembly, and packaging, allow us to bring our customers’ medical technology solutions to life. With nearly 6,000 associates across 24 locations worldwide, we are the perfect combination of big company scale and small company attention. For more information, visit